High resistance to antiretroviral drugs: The Indian experience

International Journal of STD and AIDS

Volumn 15, Issue 3, 2004, Pages 173-177

  Hira, Subhash K ^a,b,c   Panchal, Kumkum ^a   Parmar, Pooja A ^b   Bhatia, Vandana P ^b  

^a WORLD BANK   (United States)

^b SIR J J GROUP OF HOSPITALS   (India)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Antiretroviral treatment; Drug resistance; Patient monitoring

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; TISSUE CULTURE; VIRUS ISOLATION; VIRUS STRAIN;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 2442453292     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646204322916614     Document Type: Article

References (29)

1. Hoetelmans R. Pharmacological exposure and the development of drug resistance in HIV. Antivir Ther 2001;6 (Suppl 2):37-47
2. The Canadian strain and drug resistance surveillance programme. Prevalence of primary drug resistance in Canada.1997-2000. www.hc-sc.gc.ca
3. WHO (World Health Organisation). The use of Antiretroviral Therapy: A Simplified Approach for Resource constrained countries. SEA-AIDS-133 July 2002;6-10
4. Hirsch MS, Brun-Vezinet F, D Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV-1 infection: recommendations of International AIDS Society USA Panel JAMA 2000;283:2417-26
5. th Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC. Toronto, Canada, Sept 2000.Abstract 1247
6. Briones C, Perez-Olmeda M, Rodrigues C, del Romero J, Hertogs K. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid J. Acquir Immune Defic Syndr 2001;26:145-50
7. Miller V. Interpretation of resistance assay results. Antivir Ther 2001;6(Suppl 2):1-9
8. icard V, Angelini E, Maillard A, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis 2001;184:781-4
9. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Nobak NG. Full length human immunodeficiency virus type-I genomes from subtype C infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-60
10. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 2001;23:193-202
11. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr 2000;23:396-404
12. Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician-patient dialogue. AIDS 1999;13:1771-8
13. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001;15:2287-92
14. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-41
15. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999;282:1142-9
16. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral drug-resistant HIV-1 variants. Lancet 1999;354:729-33
17. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 Drug resistance among recently infected persons. JAMA 2002;288:181-8
18. Sonnerburg A, Johansson B, Ayehunie S, Julander I. Transmission of zidovudine - resistant human immunodeficiency type-1 virus. AIDS 1993;7:1684-5
19. Quigg M, Rebus S, France AJ, McMenamin J, Darby G, Leigh Brown AJ. Mutations associated with zidovudine resistance in HIV-1 among recent seroconverters. AIDS 1997;11:825-36
20. Angarano G, Monno L, Appice A, et al. Transmission of zidovudine- resistant HIV-1 through heterosexual contacts. AIDS 1994;8:1013-14
21. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994;169:411-15
22. Erice A, Mayers DL, Strike DG, et al. Primary infection with Zidovudine-resistant human immunodeficiency type 1. N Engl J Med 1993;328:1163-5
23. Fitzgibbon JE, Frenkel LD, Laraque F, Edlin BR, Dubin DT. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation. N Engl J Med 1993;329:1835-41
24. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency type 1 virus resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group. J Infect Dis 1997;175:1502-6
25. Little SI, Holte S, Routy JP, et al. Antiretroviral-Drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94
26. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type I reduces the incidence of heterosexual transmission Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994;154:1971-6
27. Murphy G, Parry JV, Jordan LF, Charlet A, Gill ON. STARHS Test shows HIV transmission continuing in UK despite widespread HAART. 14th International AIDS conference, Barcelona 2002, abs TuPeC4868.
28. World Health Organisation (WHO). Scaling up anti-retroviral therapy in resource - limited settings. Geneva: WHO; April 2002, 6
29. Brugha R. Antiretroviral treatment in developing countries, the peril of neglecting private providers. BMJ 2003;326:1382-4